BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 35896979)

  • 1. Clinical features and
    Chen D; Zhu Y; Chen Y; Zhu D; Liu Z; Li T; Liu Y; Zhao K; Su X; Li L
    BMC Infect Dis; 2022 Jul; 22(1):646. PubMed ID: 35896979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential diagnosis of lymphoma with
    Chen J; Xu D; Sun WJ; Wang WX; Xie NN; Ruan QR; Song JX
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7187-7196. PubMed ID: 36884116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (18)F-FDG and (18)F-FLT PET/CT imaging in the characterization of mediastinal lymph nodes.
    Rayamajhi SJ; Mittal BR; Maturu VN; Agarwal R; Bal A; Dey P; Shukla J; Gupta D
    Ann Nucl Med; 2016 Apr; 30(3):207-16. PubMed ID: 26661845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of diffuse lymphadenopathy via various quantitative PET/CT parameters.
    Silov G; Çankaya E; Karaçavuş S
    Hell J Nucl Med; 2023; 26(1):47-56. PubMed ID: 37031422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accuracy of F-18 FDG PET/CT with optimal cut-offs of maximum standardized uptake value according to size for diagnosis of regional lymph node metastasis in patients with rectal cancer.
    Bae SU; Won KS; Song BI; Jeong WK; Baek SK; Kim HW
    Cancer Imaging; 2018 Sep; 18(1):32. PubMed ID: 30217167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDG PET/CT radiomics as a tool to differentiate between reactive axillary lymphadenopathy following COVID-19 vaccination and metastatic breast cancer axillary lymphadenopathy: a pilot study.
    Eifer M; Pinian H; Klang E; Alhoubani Y; Kanana N; Tau N; Davidson T; Konen E; Catalano OA; Eshet Y; Domachevsky L
    Eur Radiol; 2022 Sep; 32(9):5921-5929. PubMed ID: 35385985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple metabolic parameters and visual assessment of
    Ren Y; Liu J; Wang L; Luo Y; Ding X; Shi A; Liu J
    Abdom Radiol (NY); 2020 Nov; 45(11):3569-3580. PubMed ID: 32274551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CT Texture Analysis of Cervical Lymph Nodes on Contrast-Enhanced [
    Kuno H; Garg N; Qureshi MM; Chapman MN; Li B; Meibom SK; Truong MT; Takumi K; Sakai O
    AJNR Am J Neuroradiol; 2019 Mar; 40(3):543-550. PubMed ID: 30792253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma.
    Ulaner GA; Lilienstein J; Gönen M; Maragulia J; Moskowitz CH; Zelenetz AD
    J Clin Oncol; 2014 Jan; 32(1):51-6. PubMed ID: 24248697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The incidence of thyroid cancer in focal hypermetabolic thyroid lesions: an 18F-FDG PET/CT study in more than 6000 patients.
    Barrio M; Czernin J; Yeh MW; Palma Diaz MF; Gupta P; Allen-Auerbach M; Schiepers C; Herrmann K
    Nucl Med Commun; 2016 Dec; 37(12):1290-1296. PubMed ID: 27612034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual-time-point F-18 FDG PET/CT imaging for differentiating the lymph nodes between malignant lymphoma and benign lesions.
    Nakayama M; Okizaki A; Ishitoya S; Sakaguchi M; Sato J; Aburano T
    Ann Nucl Med; 2013 Feb; 27(2):163-9. PubMed ID: 23188388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lactate dehydrogenase levels and 18F-FDG PET/CT metrics differentiate between mediastinal Hodgkin's lymphoma and primary mediastinal B-cell lymphoma.
    Alkhawtani RHM; Noordzij W; Glaudemans AWJM; van Rijn RS; van der Galiën HT; Balink H; Nijland M; Adams HJA; Huls G; van Meerten T; Kwee TC
    Nucl Med Commun; 2018 Jun; 39(6):572-578. PubMed ID: 29672465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The significance of pre-therapeutic F-18-FDG PET-CT in lymphoma-associated hemophagocytic lymphohistiocytosis when pathological evidence is unavailable.
    Wang J; Wang D; Zhang Q; Duan L; Tian T; Zhang X; Li J; Qiu H
    J Cancer Res Clin Oncol; 2016 Apr; 142(4):859-71. PubMed ID: 26666755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET/CT makes a significant contribution to diagnosis of malignancy in patients with cervical lymphadenopathy: a study using optimal scale regression tests.
    Ouyang L; Shi ZY; Lin ZG
    Chin Med J (Engl); 2013 Feb; 126(4):659-67. PubMed ID: 23422185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical value of texture analysis of dual-time-point
    Nakajo M; Jinguji M; Aoki M; Tani A; Sato M; Yoshiura T
    Eur Radiol; 2020 Mar; 30(3):1759-1769. PubMed ID: 31728684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlations between maximum standardized uptake value measured via
    Li H; Wang X; Zhang L; Yi X; Qiao Y; Jin Q
    J Cancer Res Ther; 2019; 15(7):1581-1588. PubMed ID: 31939441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-FDG PET/CT in primary brain lymphoma.
    Albano D; Bosio G; Bertoli M; Giubbini R; Bertagna F
    J Neurooncol; 2018 Feb; 136(3):577-583. PubMed ID: 29147860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative PET/CT
    Chen R; Wang Y; Zhou X; Huang G; Liu J
    Contrast Media Mol Imaging; 2018; 2018():5802109. PubMed ID: 30515068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.